JP2018514204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514204A5 JP2018514204A5 JP2017554350A JP2017554350A JP2018514204A5 JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5 JP 2017554350 A JP2017554350 A JP 2017554350A JP 2017554350 A JP2017554350 A JP 2017554350A JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- car
- signaling domain
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1507368.7 | 2015-04-30 | ||
| GBGB1507368.7A GB201507368D0 (en) | 2015-04-30 | 2015-04-30 | Cell |
| PCT/GB2016/051235 WO2016174461A1 (en) | 2015-04-30 | 2016-04-29 | T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514204A JP2018514204A (ja) | 2018-06-07 |
| JP2018514204A5 true JP2018514204A5 (enExample) | 2019-06-06 |
| JP6986449B2 JP6986449B2 (ja) | 2021-12-22 |
Family
ID=53488907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554350A Expired - Fee Related JP6986449B2 (ja) | 2015-04-30 | 2016-04-29 | ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180125890A1 (enExample) |
| EP (1) | EP3288567B1 (enExample) |
| JP (1) | JP6986449B2 (enExample) |
| KR (1) | KR20180020140A (enExample) |
| CN (1) | CN107771215A (enExample) |
| AU (1) | AU2016255611B2 (enExample) |
| BR (1) | BR112017023409A2 (enExample) |
| CA (1) | CA2982532C (enExample) |
| EA (1) | EA201792042A1 (enExample) |
| ES (1) | ES3018558T3 (enExample) |
| GB (1) | GB201507368D0 (enExample) |
| HK (1) | HK1252235A1 (enExample) |
| IL (1) | IL255186B (enExample) |
| SG (1) | SG11201708402UA (enExample) |
| WO (1) | WO2016174461A1 (enExample) |
| ZA (1) | ZA201706923B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| KR102211120B1 (ko) | 2014-05-15 | 2021-02-03 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN112695050B (zh) * | 2017-03-24 | 2025-08-08 | 莱蒂恩技术公司 | 用于用抗cd33免疫疗法治疗癌症的组合物和方法 |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CA3076817A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Tissue factor-targeting car-nk and car-t cell therapy |
| GB201715918D0 (en) | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
| GB201720949D0 (en) | 2017-12-15 | 2018-01-31 | Autolus Ltd | Cell |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019192526A1 (zh) * | 2018-04-04 | 2019-10-10 | 达仁生物科技有限公司 | 嵌合抗原受体和其治疗癌症的方法 |
| CN112004924A (zh) * | 2018-04-18 | 2020-11-27 | Ucl商务有限公司 | 增强treg细胞抑制特性的方法 |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CN110577932A (zh) * | 2018-06-07 | 2019-12-17 | 亘喜生物科技（上海）有限公司 | 一种脐带血来源的嵌合抗原受体t细胞 |
| CN119529091A (zh) * | 2018-06-19 | 2025-02-28 | 南京传奇生物科技有限公司 | 工程化的细胞及其用途 |
| TWI809130B (zh) * | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| EP3831936A4 (en) | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
| US12569507B2 (en) | 2018-08-07 | 2026-03-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T-cells for the treatment of bone metastatic cancer |
| US12156888B2 (en) | 2018-08-07 | 2024-12-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T-cells for the treatment of bone metastatic cancer |
| EP4455166A3 (en) * | 2018-08-10 | 2025-01-15 | Kyoto University | Method for producing cd3-positive cell |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| BR112021005184A8 (pt) * | 2018-09-19 | 2022-08-16 | Lava Therapeutics B V | Imunoglobulina cd1d de dupla ação |
| CN109234236A (zh) * | 2018-09-29 | 2019-01-18 | 吉林大学第医院 | 一种嵌合抗原受体γδT细胞的制备方法 |
| JP7687952B2 (ja) * | 2018-10-01 | 2025-06-03 | アディセット セラピューティクス， インク． | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| MX2021003744A (es) * | 2018-10-01 | 2021-06-23 | Adicet Bio Inc | Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos. |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| KR20210121136A (ko) * | 2019-01-29 | 2021-10-07 | 상하이 지아오통 유니버시티 | 키메라 항원 수용체 및 그 용용 |
| WO2020172555A1 (en) * | 2019-02-21 | 2020-08-27 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220162301A1 (en) * | 2019-04-12 | 2022-05-26 | PhanesTherapeutics, Inc. | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
| AU2020261886A1 (en) * | 2019-04-22 | 2021-11-18 | Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| WO2020251046A1 (ja) | 2019-06-14 | 2020-12-17 | サイアス株式会社 | 医薬組成物 |
| AU2020296197A1 (en) * | 2019-06-21 | 2022-01-20 | Shattuck Labs, Inc. | Chimeric protein expressing T-cells |
| GB201909283D0 (en) * | 2019-06-27 | 2019-08-14 | Cancer Research Tech Ltd | Fusion proteins with enzyme activity |
| CN110981972B (zh) * | 2019-12-25 | 2022-09-30 | 华夏源（上海）细胞基因工程股份有限公司 | 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用 |
| WO2021176373A1 (en) * | 2020-03-03 | 2021-09-10 | Janssen Biotech, Inc. | ꝩδ T CELLS AND USES THEREOF |
| JP7699154B2 (ja) | 2020-05-22 | 2025-06-26 | 重▲慶▼精准生物技▲術▼有限公司 | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 |
| CA3189671A1 (en) | 2020-07-17 | 2022-01-20 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| WO2023288278A1 (en) | 2021-07-16 | 2023-01-19 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
| CN113528455A (zh) * | 2021-07-19 | 2021-10-22 | 广州百暨基因科技有限公司 | 表达嵌合抗原受体的γδT细胞 |
| EP4413029A4 (en) * | 2021-10-06 | 2025-08-20 | Dana Farber Cancer Inst Inc | MODIFIED CYTOKINE RECEPTORS FOR TREATABLE ADOPTIVE CELL THERAPY |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144339A0 (en) | 1999-01-28 | 2002-05-23 | Palmetto Health Alliance | A cell line containing gamma delta lymphocytes and pharmaceutical compositions containing the same |
| JP4982645B2 (ja) | 2000-04-03 | 2012-07-25 | セラピュア バイオファーマ インコーポレーテッド | ＴｃＲガンマデルタＴ細胞の産生 |
| JP4361727B2 (ja) | 2000-09-11 | 2009-11-11 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | チロシンキナーゼインヒビターとしてのキノリノン誘導体 |
| JPWO2006006720A1 (ja) | 2004-07-13 | 2008-05-01 | 株式会社メディネット | γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤 |
| DK1778836T3 (da) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi |
| WO2008152822A1 (ja) | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2014214850C1 (en) | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| LT2958943T (lt) * | 2013-02-20 | 2020-01-27 | The Trustees Of The University Of Pennsylvania | Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3974520A1 (en) * | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3027204B1 (en) * | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| CN105848484A (zh) | 2013-10-25 | 2016-08-10 | 得克萨斯州大学系统董事会 | 用于免疫治疗的多克隆γδ T细胞 |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| MX377283B (es) * | 2013-11-21 | 2025-03-07 | Ucl Business Ltd | Célula t o nk que coexpresa un receptor antigénico quimérico (car). |
| CA3190002A1 (en) * | 2014-02-14 | 2015-08-20 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| US20170158749A1 (en) * | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| BR112017000464A2 (pt) | 2014-07-09 | 2017-11-07 | Tc Biopharm Ltd | células gama delta t e uso das mesmas |
| IL252131B2 (en) | 2014-11-17 | 2023-04-01 | Adicet Bio Inc | Transgenic gamma delta T cells |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN105158466B (zh) | 2015-05-05 | 2017-12-22 | 中国科学院广州生物医药与健康研究院 | 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法 |
-
2015
- 2015-04-30 GB GBGB1507368.7A patent/GB201507368D0/en not_active Ceased
-
2016
- 2016-04-29 JP JP2017554350A patent/JP6986449B2/ja not_active Expired - Fee Related
- 2016-04-29 SG SG11201708402UA patent/SG11201708402UA/en unknown
- 2016-04-29 WO PCT/GB2016/051235 patent/WO2016174461A1/en not_active Ceased
- 2016-04-29 ES ES16720532T patent/ES3018558T3/es active Active
- 2016-04-29 BR BR112017023409-2A patent/BR112017023409A2/en not_active Application Discontinuation
- 2016-04-29 US US15/567,165 patent/US20180125890A1/en not_active Abandoned
- 2016-04-29 AU AU2016255611A patent/AU2016255611B2/en active Active
- 2016-04-29 HK HK18111473.3A patent/HK1252235A1/zh unknown
- 2016-04-29 CN CN201680024237.0A patent/CN107771215A/zh active Pending
- 2016-04-29 CA CA2982532A patent/CA2982532C/en active Active
- 2016-04-29 KR KR1020177034648A patent/KR20180020140A/ko not_active Ceased
- 2016-04-29 EP EP16720532.7A patent/EP3288567B1/en active Active
- 2016-04-29 EA EA201792042A patent/EA201792042A1/ru unknown
-
2017
- 2017-10-12 ZA ZA2017/06923A patent/ZA201706923B/en unknown
- 2017-10-22 IL IL255186A patent/IL255186B/en unknown
-
2021
- 2021-11-17 US US17/528,836 patent/US12331316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| Lee et al. | Human γδ T cell subsets and their clinical applications for cancer immunotherapy | |
| Liu et al. | Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV | |
| JP6987134B2 (ja) | ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途 | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| Barrow et al. | Exploiting NK cell surveillance pathways for cancer therapy | |
| Seddiki et al. | Human antigen‐specific CD4+ CD25+ CD134+ CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses | |
| JP2020058380A (ja) | キメラ抗原受容体及びその製造方法 | |
| BR112021002390A2 (pt) | processos para gerar células modificadas e suas composições | |
| JP2018532407A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| JP2022541181A (ja) | Ｔｃｒ遺伝子の単離方法 | |
| JP2016538855A5 (enExample) | ||
| RU2022102250A (ru) | Клетка | |
| JP2016525873A (ja) | Ｔ細胞バランス遺伝子発現、組成物およびその使用方法 | |
| JP2018517410A5 (enExample) | ||
| CN107206024A (zh) | 改变cart细胞中的基因表达及其用途 | |
| JP2017535292A5 (enExample) | ||
| Cutmore et al. | Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer | |
| EP4458419A3 (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
| US20250154222A1 (en) | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes | |
| Lu et al. | Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation | |
| Michen et al. | Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self | |
| Chauhan et al. | Harnessing NK cell checkpoint-modulating immunotherapies | |
| CN118891290A (zh) | 细胞免疫疗法的组合物和方法 |